(S)-(1-Isopropylazetidin-2-yl)methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: (S)-(1-Isopropylazetidin-2-yl)methanol
• 英文别名: [(2S)-1-propan-2-ylazetidin-2-yl]methanol
• 化学式: C₇H₁₅NO
• 分子量: 129.2
• InChiKey: IPBIHRCLFOORQI-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1H-indole-3-carboxamide 、 (S)-(1-Isopropylazetidin-2-yl)methanol 、 氰基亚甲基三正丁基膦 生成 (S)-4-chloro-N-((4,4-difluorocyclohexyl)methyl)-1-((1-isopropylazetidin-2-yl)methyl)-1H-indole-3-carboxamide
  参考文献：
  名称：

  NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES

  摘要：

  本发明涉及吲哚化合物及其药学上可接受的组合物，用作P2X7的拮抗剂，并用于治疗与P2X7相关的疾病。

  公开号：

  US20160168090A1

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• Indole derivatives and their use in neurodegenerative diseases
  申请人：Merck Patent GmbH

  公开号：US10323000B2

  公开（公告）日：2019-06-18

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及作为 P2X7 拮抗剂和用于治疗 P2X7 相关疾病的吲哚化合物及其药学上可接受的组合物。
• SUBSTITUTED BENZOFURAN DERIVATIVES AS NOVEL ANTIMYCOBACTERIAL AGENTS
  申请人：The Texas A&M University System

  公开号：US20180111913A1

  公开（公告）日：2018-04-26

  Novel bacterial inhibitors comprising benzofuran derivatives, and methods of bacterial inhibition using the inhibitors are disclosed. The inhibitors may inhibit, for example, mycobacteria, including M. tuberculosis , by inhibition of the Pks13 enzyme. The inhibitors cmat exhibit potent whole cell and in vivo efficacy against M. tuberculosis.
• PD-1/PD-L1 INHIBITORS
  申请人：Gilead Sciences, Inc

  公开号：US20190345131A1

  公开（公告）日：2019-11-14

  Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.